strumpf

Pharma, Biotech Stocks Avoid Much Of Early New Year’s Malaise

In other news, a Food and Drug Administration advisory panel will meet Wednesday to decide whether to recommend approval for a biosimilar drug, which represents a potentially cheaper alternative to Amgen Inc. ’s Neupogen. If it gains agency approval, this drug would be the first biosimilar to get the FDA’s OK and it could mark the beginning of a new […]